FDA advisory committee today is expected to scrutinize Moderna on vaccine reaction
The FDA is recommending surveillance of Bell's palsy after four Moderna trial participants developed the temporary facial paralysis.
, Managing Editor
Sandra Lindsay, a critical care nurse at Long Island Jewish Medical Center, receives the first Pfizer-BioNTech vaccine in the U.S. on Dec. 14. (Photo courtesy Northwell Health)
In its review of the Moderna COVID-19 vaccine, the Food and Drug Administration's advisory committee today is expected to question the Bell's palsy reaction in four of its trial participants.
The FDA is recommending surveillance of Bell's palsy after three Moderna trial participants who received the vaccine and one who got a placebo developed the temporary facial paralysis that causes drooping on one side of the face.